CAN:s bibliotek

*000      am a        a
*00119992
*007cr |||||||||||
*008070120s1986||||xxu||||es|||||||||1|eng||
*24510$aPhencyclidine :$ban update
*260  $aRockville, Md :$bNational Institute on Drug Abuse,$c1986
*300  $a266 s :$bill.
*440  $aNIDA research monograph series ;$v64 
*490  $aDHHS publication ; $v86-1443
*500  $aE-bok
*5058 $aCharacterization of phencyclidine and sigma receptor-binding sites in brain. Isolation and identification of an endogenous ligand for the phencyclidine receptor. Involvement of dopaminergic, cholinergic, and glutamatergic mechanisms in the actions of phencyclidine-like drugs. Anticonvulsant properties of phencyclidine and ketamine. Agonistic and antagonistic effects of PCP-derivates and sigma opioids in PCP behavioral and receptor assays. Electroencephalographic (EEG), psychopharmacological, and receptor-binding profiles of phencyclionids. Modulation of phencyclidine (PCP) pharmacokinetics with PCP-specific fab fragments. Clinical implications of behavioral pharmacology research on phencyclidine. PCP and crime: just another illicit drug? Neuropsychological assessment of phencyclidine abusers. Phencyclidine intoxication. Diagnosis and treatment of chronic phencyclidine (PCP) abuse. Legal issues associated with PCP abuse--the role of the forensic expert. The long-term effects on neurodevelopment in infants exposed prenatally to PCP. Clinical observations in the treatment of adolescent and young adult PCP abusers.
*650 4$aPhencyclidine
*650 4$aBrain
*650 4$aRehabilitation
*650 4$aUnited States
*650 4$aNeurobiology
*650 4$aAnimals
*653  $aFencyklidin
*653  $aHjärnan
*653  $aBehandling
*653  $aUSA
*653  $aNeurokemiska aspekter
*653  $aDjurförsök
*7001 $aClovet, Doris$eed.
*7101 $aNational Institute on Drug Abuse [USA]
*85640$uhttps://archives.drugabuse.gov/sites/default/files/monograph64.pdf
^